In the search for opioid agonists with delayed antagonist actions as potential treatments for substance abuse, the bridged morphinan BU74 (17-cyclopropylmethyl-3-hydroxy-[5β,7β,3′,5′]-pyrrolidino- 2′[S]-phenyl-7α-methyl-6,14-endoetheno morphinan) (3f) was synthesized. In isolated tissue and [35S]GTPγS opioid receptor functional assays BU74 was shown to be a potent long-lasting kappa opioid receptor agonist, delta opioid receptor partial agonist and mu opioid receptor antagonist. In antinociceptive tests in the mouse, BU74 showed high efficacy and potent kappa opioid receptor agonism. When its agonist action had waned BU74 became an antagonist of kappa and mu opioid receptor agonists in the tail flick assay and of delta, kappa and mu opioid receptor agonists in the acetic acid writhing assay. The slow onset, long-duration kappa opioid receptor agonist effects of BU74 suggests that it could be a lead compound for the discovery of a treatment for cocaine abuse.
Bibliographical noteFunding Information:
This work was supported by National Institute on Drug Abuse Grants DA07315 and DA00254. The National Institute of Drug Abuse-Opioid Treatment Discovery Program provided the isolated tissue data.
Copyright 2017 Elsevier B.V., All rights reserved.
- Delayed antagonism